Shai Mulinari
1 – 10 of 93
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Drug company methodologies used for reporting in the UK pharmaceutical industry payment transparency database between 2015 and 2019 : A content analysis
(
- Contribution to journal › Article
-
Mark
Läkares jäv bör redovisas i media
2024) In Dagens Media(
- Contribution to specialist publication or newspaper › Newspaper article
-
Mark
Payments to healthcare organisations reported by the medical device industry in Europe from 2017 to 2019 : An observational study
(
- Contribution to journal › Article
-
Mark
Evaluating time to withdrawal of anti-cancer drug indications that received FDA's accelerated approval
2024) In QJM - Monthly Journal of the Association of Physicians(
- Contribution to journal › Letter
-
Mark
Patterns of company misconduct, recidivism, and complaint resolution delays : A temporal analysis of UK pharmaceutical industry self-regulation within the European context
2024) In Regulation and Governance(
- Contribution to journal › Article
-
Mark
Continued cancer drug approvals in Japan and Europe after market withdrawal in the United States : A comparative study of accelerated approvals
(
- Contribution to journal › Article
-
Mark
Broken beyond repair: self regulation of industry payments to clinicians and hospitals
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Delays in dealing with complaints against drug companies are growing, BMJ finds
(
- Contribution to specialist publication or newspaper › Specialist publication article
- 2023
-
Mark
Conceptual unclarity about COVID-19 ethnic disparities in Sweden: Implications for public health policy
(
- Contribution to journal › Article
-
Mark
Race in clinical trials in Sweden: how regulatory and medical standards in clinical research trump the post-racial discourse
2023) In Sociology of Health & Illness(
- Contribution to journal › Article